S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:INMB

INmune Bio Competitors

$15.37
-3.46 (-18.37 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.64
Now: $15.37
$18.80
50-Day Range
$16.22
MA: $20.18
$26.85
52-Week Range
$2.20
Now: $15.37
$29.99
Volume318,963 shs
Average Volume386,399 shs
Market Capitalization$206.70 million
P/E RatioN/A
Dividend YieldN/A
Beta3.01

Competitors

INmune Bio (NASDAQ:INMB) Vs. ALGS, CLLS, TCRR, STRO, ADAP, and VXRT

Should you be buying INMB stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to INmune Bio, including Aligos Therapeutics (ALGS), Cellectis (CLLS), TCR2 Therapeutics (TCRR), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), and Vaxart (VXRT).

INmune Bio (NASDAQ:INMB) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Earnings & Valuation

This table compares INmune Bio and Aligos Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune BioN/AN/A$-7,680,000.00($0.75)-20.49
Aligos TherapeuticsN/AN/AN/AN/AN/A

Insider & Institutional Ownership

7.4% of INmune Bio shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares INmune Bio and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INmune BioN/A-41.18%-39.34%
Aligos TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for INmune Bio and Aligos Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INmune Bio00403.00
Aligos Therapeutics00403.00

INmune Bio currently has a consensus target price of $19.25, suggesting a potential upside of 25.24%. Aligos Therapeutics has a consensus target price of $30.50, suggesting a potential upside of 41.60%. Given Aligos Therapeutics' higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than INmune Bio.

Summary

Aligos Therapeutics beats INmune Bio on 3 of the 5 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Volatility and Risk

Cellectis has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cellectis and INmune Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million35.69$-102,090,000.00($2.41)-8.01
INmune BioN/AN/A$-7,680,000.00($0.75)-20.49

INmune Bio has lower revenue, but higher earnings than Cellectis. INmune Bio is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Cellectis and INmune Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11302.40
INmune Bio00403.00

Cellectis currently has a consensus price target of $24.25, indicating a potential upside of 25.58%. INmune Bio has a consensus price target of $19.25, indicating a potential upside of 25.24%. Given Cellectis' higher possible upside, analysts plainly believe Cellectis is more favorable than INmune Bio.

Insider & Institutional Ownership

33.3% of Cellectis shares are held by institutional investors. Comparatively, 7.4% of INmune Bio shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 58.9% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Cellectis and INmune Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
INmune BioN/A-41.18%-39.34%

Summary

INmune Bio beats Cellectis on 7 of the 13 factors compared between the two stocks.

INmune Bio (NASDAQ:INMB) and TCR2 Therapeutics (NASDAQ:TCRR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

INmune Bio has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500. Comparatively, TCR2 Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.

Institutional & Insider Ownership

7.4% of INmune Bio shares are held by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are held by institutional investors. 58.9% of INmune Bio shares are held by company insiders. Comparatively, 28.0% of TCR2 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for INmune Bio and TCR2 Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INmune Bio00403.00
TCR2 Therapeutics00703.00

INmune Bio currently has a consensus price target of $19.25, indicating a potential upside of 25.24%. TCR2 Therapeutics has a consensus price target of $39.2857, indicating a potential upside of 63.28%. Given TCR2 Therapeutics' higher possible upside, analysts clearly believe TCR2 Therapeutics is more favorable than INmune Bio.

Valuation and Earnings

This table compares INmune Bio and TCR2 Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune BioN/AN/A$-7,680,000.00($0.75)-20.49
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21

INmune Bio is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares INmune Bio and TCR2 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INmune BioN/A-41.18%-39.34%
TCR2 TherapeuticsN/A-35.51%-34.02%

Summary

TCR2 Therapeutics beats INmune Bio on 6 of the 10 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Sutro Biopharma and INmune Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
INmune Bio00403.00

Sutro Biopharma currently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. INmune Bio has a consensus target price of $19.25, indicating a potential upside of 25.24%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts clearly believe INmune Bio is more favorable than Sutro Biopharma.

Profitability

This table compares Sutro Biopharma and INmune Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
INmune BioN/A-41.18%-39.34%

Volatility & Risk

Sutro Biopharma has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sutro Biopharma and INmune Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
INmune BioN/AN/A$-7,680,000.00($0.75)-20.49

INmune Bio has lower revenue, but higher earnings than Sutro Biopharma. INmune Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 7.4% of INmune Bio shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by company insiders. Comparatively, 58.9% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

INmune Bio beats Sutro Biopharma on 8 of the 13 factors compared between the two stocks.

INmune Bio (NASDAQ:INMB) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares INmune Bio and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INmune BioN/A-41.18%-39.34%
Adaptimmune Therapeutics-3,858.14%-44.94%-33.70%

Analyst Recommendations

This is a summary of current ratings and recommmendations for INmune Bio and Adaptimmune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INmune Bio00403.00
Adaptimmune Therapeutics03202.40

INmune Bio currently has a consensus target price of $19.25, suggesting a potential upside of 25.24%. Adaptimmune Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 209.38%. Given Adaptimmune Therapeutics' higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than INmune Bio.

Valuation and Earnings

This table compares INmune Bio and Adaptimmune Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune BioN/AN/A$-7,680,000.00($0.75)-20.49
Adaptimmune Therapeutics$1.12 million692.36$-137,160,000.00($1.32)-3.80

INmune Bio has higher earnings, but lower revenue than Adaptimmune Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.4% of INmune Bio shares are held by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are held by institutional investors. 58.9% of INmune Bio shares are held by company insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

INmune Bio has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Summary

INmune Bio beats Adaptimmune Therapeutics on 8 of the 13 factors compared between the two stocks.

Vaxart (NASDAQ:VXRT) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vaxart and INmune Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxart00203.00
INmune Bio00403.00

Vaxart currently has a consensus price target of $15.00, suggesting a potential upside of 153.38%. INmune Bio has a consensus price target of $19.25, suggesting a potential upside of 25.24%. Given Vaxart's higher possible upside, equities analysts plainly believe Vaxart is more favorable than INmune Bio.

Insider & Institutional Ownership

17.9% of Vaxart shares are held by institutional investors. Comparatively, 7.4% of INmune Bio shares are held by institutional investors. 7.3% of Vaxart shares are held by company insiders. Comparatively, 58.9% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Vaxart and INmune Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vaxart-281.50%-84.90%-44.67%
INmune BioN/A-41.18%-39.34%

Volatility and Risk

Vaxart has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vaxart and INmune Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaxart$9.86 million70.71$-18,650,000.00($0.86)-6.88
INmune BioN/AN/A$-7,680,000.00($0.75)-20.49

INmune Bio has lower revenue, but higher earnings than Vaxart. INmune Bio is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Summary

INmune Bio beats Vaxart on 8 of the 12 factors compared between the two stocks.


INmune Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
Axcella Health logo
AXLA
Axcella Health
1.6$5.51-3.1%$206.85 millionN/A-2.56
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43-6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
Genfit logo
GNFT
Genfit
1.3$4.87-2.7%$189.24 million$45.88 million-2.47
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.18-6.7%$186.70 millionN/A-8.76Gap Up
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$4.23-14.2%$178.75 million$1.45 million-1.48Earnings Announcement
Analyst Upgrade
Increase in Short Interest
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.90-0.7%$178.60 millionN/A-2.27Gap Up
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$5.35-4.3%$168.68 million$20,000.000.00Decrease in Short Interest
Gap Down
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.